Prof. Dr. Koen Kas is a healthcare futurist, delight thinker, professor of Molecular Oncology & Digital Health, and leading international keynote speaker addressing healthcare innovation, digital health and patient / organisation delight.

He published his vision in two books: ‘Sick No More’ describes how we will transition from reactive sick care to predictive, proactive and personalised healthcare. ‘Your Guide to Delight’ is a roadmap towards that future, introducing our personal digital twin that will keep you, and your company, relevant and “young”. Koen will soon launch his third book, EPIC — exploring the idea that health is not merely the absence of disease, but the foundation for purpose, performance, and legacy. It weaves together healthtech and AI, longevity science, and the power of art and creativity to become truly Epic.

As founding CEO of Healthskouts, a digital health advisory company, Koen works with global pharmaceutical companies, technology companies, hospitals and governments to help them see the digital health landscape with greater clarity, to sharpen strategy and bring delightful products and services to market faster. Healthskouts also curates one of the world’s leading databases of certified digital health solutions. 

Koen is guest professor at Ghent University in Belgium. He is Chairman of the European Cancer Prevention Organisation; Co-chair of the Digital Twin Consortium healthcare workgroup; Advisor of the Digital Therapeutics Alliance; Ambassador of Health House and VITO’s We Are project on decentralized health data (using Solid – a complete reinvention of the internet); Jury of the Prix Galien; and sits on the advisory board of 5 emerging (digital) healthcare companies and two startup accelerators.

Earlier, Koen was CSO Oncology at Oxurion, where he developed a novel drug for pediatric brain cancer. Before this, he was founder and CSO of Pronota, building a protein biomarker discovery platform and pipeline of four diagnostic programs. Prior to that, he was the director of drug discovery at Galapagos. Previously he set up and directed the cancer drug discovery program at Tibotec (now Johnson & Johnson). He started his career elucidating the molecular basis of two types of cancers.